Fangji Powder Veterinary Grade API is the dried and comminuted root material of Stephania tetrandra S. Moore, standardized by reverse-phase HPLC to the bisbenzylisoquinoline alkaloid markers tetrandrine and fangchinoline. The material is supplied as a multi-dosage-form botanical input for tablets, capsules, direct powders, granules, premixes, and oral solutions. It is not, in its whole-powder state, an injectable API. Parenteral use requires subsequent extraction, purification, depyrogenation, and sterile filtration because crude botanical particles and endotoxin levels exceed the acceptance criteria of USP <85> and USP <788>. No unified pharmacopoeial model code governs the trade designation. Procurement should therefore be tied to a vendor-specific grade code that is traceable to the botanical source, harvesting lot, milling campaign, and analytical certificate.

The first critical control is botanical identity because Stephania tetrandra Fangji has been confused with Aristolochia fangchi, the aristolochic-acid-containing Guang Fangji. Identity confirmation must include macroscopic and microscopic examination, HPTLC or LC-MS/MS, and an aristolochic acid I and II method with a reporting limit not exceeding 1 ppm. The absence of aristolochic acid markers is a release criterion, not merely an informational observation. Assay should quantify tetrandrine and fangchinoline by reversed-phase HPLC using a C18 column and UV detection near 280 nm. Vendor-specific model numbers typically encode mesh cut and washing status, but the model designation alone is insufficient evidence of compendial compliance without the accompanying certificate of analysis.

Fangji Powder Veterinary API: Specification Parameters and Release Limits

Release limits are derived from botanical monograph requirements and the intended final dosage form. Loss on drying at 105 °C is generally controlled at ≤10.0%, total ash at ≤8.0%, and acid-insoluble ash at ≤2.0% when tested under USP <731> and USP <561>. Elemental impurity screening should include lead ≤5.0 ppm, cadmium ≤0.5 ppm, arsenic ≤2.0 ppm, and mercury ≤0.1 ppm; the exact acceptance limits must be adjusted to the target veterinary species and the daily dose. Microbial enumeration under USP <2021> should meet total aerobic microbial count ≤10⁴ CFU/g, total yeast and mold count ≤10² CFU/g, absence of Escherichia coli in 1 g, and absence of Salmonella in 25 g for oral powders and premixes. If the powder is intended for extraction into an injectable fraction, the whole-powder microbial limits do not replace finished parenteral requirements.

Method reproducibility for the botanical API should consider the natural tetrandrine-to-fangchinoline ratio. Co-elution or peak fronting on short C18 columns can bias total alkaloid values; a column with 5 µm packing and 250 × 4.6 mm dimensions, with system suitability resolution not less than 1.5 between tetrandrine and fangchinoline, is appropriate. Injection precision should show relative standard deviation ≤1.0% for replicate standards. Assay acceptance for total markers may be set at ±10% of the vendor-validated mean unless the final veterinary drug product claims a different label basis. Stability-indicating HPLC should include resolution of tetrandrine from fangchinoline and from any forced-degradation peak; published data for this specific veterinary grade configuration are limited.

Acceptance criteria for particle-size distribution should be established by laser diffraction rather than sieve alone when the powder is intended for suspensions. A D90 of ≤200 µm is usually satisfactory for oral powders; for oral suspensions, a D90 ≤50 µm improves syringability and reduces settling. Bulk density and tapped density should be part of the release protocol. Loose bulk density is expected to vary between 0.35 g/cm³ and 0.55 g/cm³; the Carr index should be below 30 for direct compression. If the Carr index exceeds 30, a glidant should be included before tableting or encapsulation.

What Limits Direct Compression of Fangji Powder in Tablet Blends?

Fangji Powder behaves as a fibrous botanical material with high elastic recovery after compression. Direct compression is feasible only if the formulation absorbs the plant matrix and controls moisture. On a 10-station rotary tablet press, a validated blend may contain microcrystalline cellulose at 20–30%, croscarmellose sodium at 2–5%, and colloidal silicon dioxide at 0.5–1.0%. Compression force is typically titrated between 8 kN and 15 kN; force above 15 kN may cause capping because the elastic energy of the botanical fiber prevents stable bonding. Residual moisture below 3% can worsen lamination, while moisture above 12% can cause picking and sticking. The formulation must satisfy disintegration under USP <701> and friability ≤1.0% under USP <1216>.

Granulation before tableting is often preferred over direct compression because the wet massing step densifies fibrous particles and reduces segregation. Povidone K30 at 3–5% solids is used as a binder; the wet mass is passed through a 14-mesh screen and dried in a fluid-bed dryer with inlet air temperature not exceeding 60 °C. Drying to residual moisture ≤5.0% is considered stable for aqueous granulation; the dried granules are milled to 16–40 mesh (425–1180 µm). Total alkaloid recovery should be checked after drying and should be ≥95% of the pre-drying value. Prolonged tray drying above 60 °C may reduce marker recovery; process qualification must verify assay recovery on a batch-by-batch basis.

Encapsulation on a dosator machine requires that the granulated or powder blend have a bulk density between 0.4 g/cm³ and 0.6 g/cm³ and a compressibility index below 20. Magnesium stearate addition should not exceed 1.0% and mixing time should be limited to 3–5 minutes; overlubrication coats alkaloid particles and delays release. HPMC capsule shells should be filled at ambient relative humidity below 60%; higher relative humidity can cause shell deformation and dosator plugging. Weight variation should be verified under USP <905> for the selected capsule size.

Injectable-Grade Requirements and the Unsuitability of Whole Botanical Powder

Whole Fangji powder is not appropriate for injectable solutions. The raw botanical matrix contains insoluble fibers, bacterial endotoxins, and extractives that are incompatible with intravenous or intramuscular routes. An injectable product must be prepared from a purified alkaloid fraction or isolated tetrandrine hydrochloride, with controlled pH, tonicity, and preservative levels. Sterile filtration through 0.22 µm is not a depyrogenation operation; endotoxin removal must be performed by validated ultrafiltration, ion-exchange chromatography, or other depyrogenation techniques. The final solution must meet sterility under USP <71>, particulate matter under USP <788>, and dose-specific endotoxin limits under USP <85>.

If the powder is used as the extraction source for an injectable, the manufacturing route should include water or aqueous ethanol extraction, ethanol precipitation or liquid-liquid extraction, and purification of the total alkaloid fraction. Residual solvent compliance follows USP <467> or VICH GL18. The purified fraction should have a defined tetrandrine and fangchinoline ratio, low non-alkaloid extractives, and controlled heavy metals. Published data for this specific botanical configuration are limited; the injectable process must be validated under the target species and route of administration.

When Fangji Powder Is Converted to Oral Solutions and Reconstituted Premixes

Oral solutions and drench formulations are prepared by extracting the powder in water or aqueous ethanol at a fixed extraction ratio. Extraction at 40–60 °C for 2–4 hours balances marker transfer against extraction of polymeric polysaccharides and tannins. The extract is then clarified through 10 µm polypropylene bag filters. If a multi-dose solution is produced, antimicrobial preservation is tested by USP <51>. Settling studies over 72 hours are used to assess the need for a suspending agent; a sedimentation volume below 0.9 may require carbomer or microcrystalline cellulose stabilizers. In aqueous media, the bisbenzylisoquinoline alkaloids have low solubility as free bases; salt formation or a buffered acidic vehicle may be required to maintain clarity.

Premix manufacture for feed addition requires pre-blending with a carrier that matches the bulk density of Fangji Powder. Calcium carbonate or defatted rice bran is often selected; however, the carrier choice must be tested because alkaloid adsorption onto calcium carbonate can slow marker extraction and bias blend uniformity samples. If the carrier mean diameter is more than 5 times the active mean diameter, sifting segregation may occur. A 10-minute blend with sampling at 5, 10, and 15 minutes should show active marker content uniformity within ±10% of target before transfer to production batches. The powder should be packaged in double food-grade polyethylene bags within an HDPE drum, with desiccant if ambient relative humidity exceeds 60%.

Differentiating Whole Fangji Powder from Isolated Alkaloids and Aristolochia-Containing Substitutes

The principal safety distinction is the absence of aristolochic acids in Stephania tetrandra Fangji powder compared with Aristolochia fangchi Guang Fangji. Misidentification can be detected by HPTLC or LC-MS/MS; a reporting limit of 1 ppm for aristolochic acid I and II should be maintained because nephrotoxic risk is not acceptable at any pharmacologically meaningful level. The whole powder also differs from isolated tetrandrine: the powder contains multiple isoquinoline alkaloids, plant polysaccharides, and ash, while isolated tetrandrine is a single-marker API with higher purity and tighter dose control. Concentrated extracts differ from the raw powder by reduced insoluble matrix, higher alkaloid concentration, and often higher hygroscopicity. For tablet, capsule, and premix formulation, whole powder may be selected when the final label is based on whole-herb equivalency; isolated or purified fractions are selected for injectable or high-load solid-dose products.

Storage conditions for unopened Fangji Powder should be below 25 °C and 60% relative humidity. The powder is hygroscopic; if moisture rise above 10.0% is observed in the warehouse, drying in a 40 °C forced-air oven may be required before processing. Combination with strong oxidizing agents, hypochlorite, or tannin-rich co-extracts may reduce alkaloid recovery or cause precipitate formation. Forced-degradation studies should be used to establish acceptable pH and temperature boundaries for each formulation. A 24-month real-time stability program supporting retest intervals is appropriate; published data for this exact product designation are limited, and release limits must be confirmed under the applicant’s process validation.